NASDAQ · LBRX
LB Pharmaceuticals Inc Common Stock
$40.15+$0.32 (+0.8%)
LB Pharmaceuticals Inc Common Stock’s quoted price sits in the upper half of its reported 52-week range, 19.96% below the high.
Loading market information…
NASDAQ · NBP · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
NovaBridge Biosciences’s quoted price sits in the lower half of its reported 52-week range, 76.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
NovaBridge Biosciences’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow NovaBridge Biosciences’s reporting calendar.
THE COMPANY BEHIND THE TICKER
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 | Nov 14, 2024 | -$0.25-56.25% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q2 2024 | Aug 28, 2024 | -$0.07+86.27% vs estimate | $9.86M+557.17% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$40.15+$0.32 (+0.8%)
LB Pharmaceuticals Inc Common Stock’s quoted price sits in the upper half of its reported 52-week range, 19.96% below the high.
$13.23-$0.12 (-0.9%)
Alpha Tau Medical Ltd’s quoted price sits in the upper half of its reported 52-week range, 16.21% below the high.
$11.06-$0.02 (-0.18%)
Design Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.88% below the high.
$4.01-$0.03 (-0.74%)
Annexon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.15% below the high.
$6.30-$0.11 (-1.64%)
Aura Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.01% below the high.
$9.52-$0.30 (-3.05%)
DiaMedica Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.64% below the high.
$2.14+$0.04 (+1.9%)
Altimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.77% below the high.
$2.54-$0.04 (-1.55%)
Rocket Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.39% below the high.
